STOCK TITAN

Eli Lilly Form 144: $223.7M stock sale equals 0.03% of float

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Eli Lilly & Co. (LLY) filed a Form 144 notice for the proposed sale of restricted shares.

  • Seller intends to dispose of 280,000 common shares through Fidelity Capital Markets.
  • At the filing’s reference price, the block is worth $223.7 million.
  • Eli Lilly has 947.7 million shares outstanding, so the sale represents roughly 0.03 % of the float—small in relation to daily liquidity and unlikely to be dilutive.
  • Planned trade date: 24 Jul 2025; exchanges listed: NYSE / NASDAQ.
  • The shares trace back to a 10 Feb 1948 gift from the J.K. Lilly Sr. Trust; no other sales were reported in the past three months.

The filer certifies awareness of no undisclosed material adverse information.

Positive

  • None.

Negative

  • $223.7 million insider sale could create short-term sentiment pressure despite its small 0.03 % share of outstanding stock.

Insights

TL;DR: $224 m sale equals 0.03 % of float—immaterial to valuation, modest sentiment risk.

The proposed divestiture is minor relative to LLY’s market cap and share count, so supply overhang and dilution concerns are negligible. Because the shares were originally gifted decades ago, the transaction likely reflects estate or liquidity planning, not operational insight. The market could interpret any sizable dollar amount as insider bearishness, but volume-adjusted impact should be limited.

TL;DR: Routine Form 144 filing; compliance posture intact, governance impact minimal.

Form 144 signals transparency around restricted-stock disposal. The signer affirms no undisclosed adverse information, reducing litigation risk. Absence of prior 3-month sales suggests adherence to Rule 144 volume limits. Given the sale’s small percentage, no board or shareholder approval issues arise, and fiduciary considerations remain standard.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many LLY shares are being sold under this Form 144?

The filing covers 280,000 common shares.

What is the aggregate market value of the proposed LLY share sale?

The block is valued at approximately $223.7 million.

When is the expected sale date for the LLY shares?

The approximate sale date disclosed is July 24, 2025.

On which exchange will the LLY shares be sold?

The filing lists NYSE and NASDAQ as the target exchanges.

What percentage of Eli Lilly’s outstanding shares does the sale represent?

About 0.03 % of the 947.7 million shares outstanding.

Who is the broker handling the transaction?

The broker of record is Fidelity Capital Markets, 640 Fifth Avenue, New York.

What is the origin of the shares being sold?

They were acquired as a gift on February 10, 1948 from the J.K. Lilly Sr. Trust.